Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph+) leukemias resistant or intolerant to imatinib.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2275129310